⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2440995 | 0.74 | — | — | |
| SCHEMBL8042854 | 0.73 | — | — | |
| SCHEMBL18542005 | 0.72 | SMN1; SMN2 (0.51) | — | |
| SCHEMBL9893162 | 0.72 | CA1 (0.53) | — | |
| SCHEMBL2442388 | 0.72 | SMN1; SMN2 (0.41) | — | |
| SCHEMBL14501008 | 0.71 | CA2 (0.58) | — | |
| SCHEMBL2441632 | 0.70 | SMN1; SMN2 (0.40) | — | |
| SCHEMBL17120465 | 0.69 | — | — | |
| SCHEMBL10896731 | 0.69 | — | — | |
| SCHEMBL2445764 | 0.68 | GLS (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275022-A1 | Substituted Quinazolones as Anti-Cancer Agents | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | US | claimed |
| EP-1761506-A1 | SUBSTITUTED QUINAZOLONES AS ANTI-CANCER AGENTS | AstraZeneca AB (SE) | 2007-03-14 | — | — | EP | claimed |
| WO-2005123696-A1 | SUBSTITUTED QUINAZOLONES AS ANTI-CANCER AGENTS | ASTRAZENECA AB (SE) | 2005-12-29 | — | — | WO | claimed |
| US-6852752-B2 | Urea compounds, compositions and methods of use and preparation | VICURON PHARMACEUTICALS INC. (US) | 2005-02-08 | — | — | US | claimed |
| US-20020119962-A1 | Novel urea compounds, compositions and methods of use and preparation | VICURON HOLDINGS LLC | 2002-08-29 | — | — | US | claimed |
| WO-2001044178-A1 | NOVEL UREA COMPOUNDS, COMPOSITIONS AND METHODS OF USE AND PREPARATION | VERSICOR, INC. (US) | 2001-06-21 | — | — | WO | claimed |
| US-20120107273-A1 | NEW PIPERAZINE COMPOUND AND USE THEREOF AS A HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-05-03 | — | — | US | disclosed |
| US-8017612-B2 | therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors | JAPAN TOBACCO INC. (JP) | 2011-09-13 | — | — | US | disclosed |
| EP-2009004-A1 | NOVEL PIPERAZINE COMPOUND, AND USE THEREOF AS HCV POLYMERASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2008-12-31 | — | — | EP | disclosed |
| US-20080275022-A1 | Substituted Quinazolones as Anti-Cancer Agents | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | US | disclosed |
| US-20080081818-A1 | therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors | JAPAN TOBACCO INC. (JP) | 2008-04-03 | — | — | US | disclosed |
| EP-1761506-A1 | SUBSTITUTED QUINAZOLONES AS ANTI-CANCER AGENTS | AstraZeneca AB (SE) | 2007-03-14 | — | — | EP | disclosed |
| WO-2005123696-A1 | SUBSTITUTED QUINAZOLONES AS ANTI-CANCER AGENTS | ASTRAZENECA AB (SE) | 2005-12-29 | — | — | WO | disclosed |
| US-20020119962-A1 | Novel urea compounds, compositions and methods of use and preparation | VICURON HOLDINGS LLC | 2002-08-29 | — | — | US | disclosed |
| WO-2001044178-A1 | NOVEL UREA COMPOUNDS, COMPOSITIONS AND METHODS OF USE AND PREPARATION | VERSICOR, INC. (US) | 2001-06-21 | — | — | WO | disclosed |
| EP-0457195-B1 | Peptides having endothelin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same | FUJISAWA PHARMACEUTICAL CO (JP) | 1998-04-15 | — | — | EP | disclosed |
| US-5656604-A | HYPOTENSIVE AGENT; ENDOTHELIN ANTAGONIST | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-08-12 | — | — | US | disclosed |
| US-5430022-A | Endothelin antagonists; hypotensive agents; treatment for angina pectoris, brain disorders, asthma, renal failure | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-07-04 | — | — | US | disclosed |
| US-5284828-A | Hypotensive agents | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 1994-02-08 | — | — | US | disclosed |
| EP-0457195-A2 | Peptides having endothelin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-11-21 | — | — | EP | disclosed |